BioSpace News Archive

ISTURISA® (osilodrostat) demonstrates significant and sustained benefit over placebo at normalizing mean urinary free cortisol (mUFC) levels in patients with Cushing’s disease

T2 Biosystems, Inc. announced that on June 16, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC stating that the Company regained compliance with the applicable Nasdaq minimum bid price continued listing requirement and the matter is now closed.

Geisinger Wyoming Valley Medical Center is First in the World to Treat Patients with the New System

Initiation of randomized, double-blind, placebo-controlled Phase II trial of merimepodib, an orally administered broad-spectrum anti-viral, in combination with intravenous remdesivir in patients with advanced COVID-19 (hospitalized and requiring oxygen)

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that clinical outcomes data from the open-label treatment protocol with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor rece

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of two senior executives to the leadership team. Filip Dubovsky, M.D., MPH, FAAP, has been appointed Senior Vice President and Chief Medical Officer, where he will oversee Novavax’ medical and clinical affairs and related activities. Novavax also appointed Silvia Taylor, MBA, as

Global leader in fertility treatment increases access to successful outcomes by offering the Assure IVF Refund Program and Multi-Cycle Program

- Respira announces plans to pursue FDA authorization of the RespiRxTM drug delivery platform as the first vapor style inhalable Nicotine Replacement Therapy (NRT) designed to significantly increase cessation therapy effectiveness in the U.S. - RespiRxTM is a breakthrough medical nebulizer with broad application for the delivery of thermo and pressure sensitive drug complexes across multiple target markets [17-June-2020]

United Therapeutics Corporation announced that key data from the INCREASE study of Tyvaso® Inhalation Solution in patients suffering from World Health Organization Group 3 pulmonary hypertension associated with interstitial lung disease will be presented at a Breaking News Session hosted by the American Thoracic Society on June 24, 2020.

Serology test achieves 99.9% sensitivity and 99.5% specificity for SARS CoV-2; ProMIS proprietary peptide antigens to detect neutralizing antibodies in next development phase